Современные возможности диагностики и лечения диффузной В-крупноклеточной лимфомы у детей и взрослых (обзор литературы)


Цитировать

Полный текст

Аннотация

Диффузная В-крупноклеточная лимфома (ДВККЛ) включает разные варианты заболевания, гетерогенные по клиническим, морфологическим, иммунологическим, цитогенетическим и молекулярно-биологическим параметрам. В данной статье представлены результаты лечения детей и взрослых с ДВККЛ по различным программам (AIEOP NHL92, B-NHL-BFM90, POG APO - IDM/HiDAC, B-NHL-BFM95, FAB/LMB96, BNHL03, FAB/LMB96 + ритуксимаб, Б-НХЛ2004м + ритуксимаб, R-CHOP, DA-EPOCH-R, RB-CHOP, RBV-CHOP). Выделены молекулярно-биологические факторы неблагоприятного прогноза заболевания у взрослых пациентов с ДВККЛ, которые позволят улучшить стратификацию групп риска, уменьшить интенсивность проводимой терапии у некоторых пациентов, но в настоящее время требуют дополнительного изучения у детей. Особое внимание уделено изучению чувствительности опухоли к таргетной терапии, в частности к анти-CD20 моноклональным антителам.

Об авторах

А С Левашов

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России

Email: andreyslevashov@mail.ru
науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Россия, Москва, Каширское ш., д. 23

Т Т Валиев

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России

канд. мед. наук, ст. науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Россия, Москва, Каширское ш., д. 23

А М Ковригина

ФГБУ Гематологический научный центр Минздрава России

д-р биол. наук, проф., зав. патологоанатомическим отд-нием ФГБУ ГНЦ 125167, Россия, Москва, Новый Зыковский пр., д. 4

А В Попа

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России

д-р мед. наук, зав. отд-нием химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Россия, Москва, Каширское ш., д. 23

Г Л Менткевич

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России

д-р мед. наук, проф., зав. отд. химиотерапии НИИ детской онкологии и гематологии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Россия, Москва, Каширское ш., д. 23

Список литературы

  1. Reiter A et al. Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. Hematology 2007; 1: 285-96.
  2. Burkhardt В, Oschlies I, Klapper W et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011; 25: 153-60.
  3. Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. М.: МИА, 2007; с. 212.
  4. Swerdlow S.H, Campo E, Harris N.L et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2008.
  5. Reiter A et al. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Hematol 2008; 142: 329-47.
  6. Jaffe E.S et al. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. Hematology 2011; 506-14.
  7. Heerema N.A, Bernheim A.B, Lim M.S et al. Meeting report, State of the art and future needs in cytogenetic/molecular genetics/arrays in childhood lymphoma: summary report of workshop at the first international symposium on childhood and adolescent non-Hodgkin lymphoma. Ped Blood Cancer 2005; 45: 616-22.
  8. Oschlies I et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal - center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Francfurt-Munster) multicenter trial. Blood 2006; 107 (10): 4047-52.
  9. Miles R, Raphael M, Mc Carthy et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c - myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) International Study Group. Ped Blood Cancer 2008; 51 (3): 369-74.
  10. Валиев Т.Т., Морозова О.В., Ковригина А.М. и др. Диагностика и лечение анапластических крупноклеточных лимфом у детей. Гематология и трансфузиология. 2012; 51 (1): 3-9.
  11. Барышников А.Ю., Валиев Т.Т., Губин А.Н. Лимфомы у детей: практ. рук. Под ред. Г.Л.Менткевича, С.А.Маяковой. М.: Практическая медицина, 2014.
  12. Pillon M et al. Long - term results of the first Italian association of pediatric hematology and oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 2004; 101 (2): 385-94.
  13. Reiter A, Schrappe M, Tieman M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster group Trial NHL-BFM90. Blood 1999; 94 (10): 3294-306.
  14. Laver J.H, Kraveka J.M, Hutchison R.E et al. Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial. J Clin Oncol 2005; 23 (3): 541-7.
  15. Woessmann W, Seidemann K, Mann G et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood 2005; 105 (3): 948-58.
  16. Cairo M, Sposto R, Gerrard M. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescents age (>15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol 2012; 30 (4): 387-93.
  17. Patte C, Auperin A, Gerard M et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-80.
  18. Gerrard M, Waxman I.M, Sposto R et al. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. Blood 2013; 121 (2): 278-85.
  19. Worth J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents - review of standartd chemotherapy regimen and perspectives. Ped Hematol Oncol 2013; 30: 465-83.
  20. Tsurusawa M, Mori T, Kikuchi A et al. Improved treatment results of Children with B-cell non-Hodgkin lymphoma: a report from Japanese pediatric leukemia/lymphoma study group B-NHL03 study. Ped Blood Cancer 2014; 61: 1215-21.
  21. Goldman S, Smith L, Anderson J.R et al. Rituximab and FAB/LMB96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology group report. Leukemia 2013; 27: 1174-7.
  22. Barth M.J, Goldman S, Smith L et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukemia: a Children’s Oncology group report. Br J Haematol 2013; 162: 678-83.
  23. Самочатова Е.В., Шелихова Л.Н., Мякова Н.В. Лечение диффузной Б-крупноклеточной лимфомы у детей с применением интенсивной химиотерапии с ритуксимабом: предварительные результаты. Детская онкология. 2007; 3-4: 51-6.
  24. Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ2004м с применением ритуксимаба и модифицированного протокола Б-НХЛ БФМ 90. Онкогематология. 2009; 3: 4-14.
  25. Самочатова Е.В., Шелихова Л.Н., Мякова Н.В. Возможности и проблемы современной терапии неходжкинских лимфом у детей и подростков. Педиатрия. 2011; 90 (4): 37-43.
  26. Lange J et al. Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. Curr Hematol Malig Rep 2013; 8 (3): 226-35.
  27. Meinhardt A, Burkhardt B, Zimmermann M et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt Leukemia. J Clin Oncol 2010; 28 (19): 3115-21.
  28. Meyer P.N, Fu K, Greiner T.G et al. Immunohistocemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011; 29 (2): 200-7.
  29. Hu S, Xu-Monette Z.Y, Tzankov A et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high - risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood 2013; 121 (20): 4021-31.
  30. Wilson W.H, Jung S.H et al. A cancer and leukemia group B multi - center study of DA-EPOCH - rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Hematologyca 2012; 97 (5): 758-65.
  31. Нечунаева И.Н., Агеева Т.А., Маслова Л.М. Эффективность лечения диффузных В-клеточных крупноклеточных лимфом по данным городского гематологического центра г. Новосибирска. Бюллетень СО РАМН. 2011; 31 (2): 71-4.
  32. Klapper W, Kreuz M, Kohler C.W et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 2012; 119 (8): 1882-7.
  33. Chen Y, Sun X.F, Cai R.Q. Germinal - center type B-cell classification and clinical characteristics of Chinese pediatric diffuse large B-cell lymphoma: a report of 76 cases. Chin J Cancer 2013; 32 (10): 561-6.
  34. Poirel H.A, Cairo M.S, Heerema N.A et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia 2009; 23 (2): 323-31.
  35. Hans C.P, Weisenburger D.D, Greiner T.C et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immuhistochemistry using a tissue microarray. Blood 2004; 103 (1): 275-82.
  36. Hoeller S, Schneider A, Haralambieva E et al. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non - germinal centre phenotype, indepemdent of gains and structural aberrations at 3p14.1. Histopathology 2010; 57: 73-80.
  37. Perry A.M, Zdravko M et al. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 2012; 19 (3): 214-26.
  38. Culpin R.E, Sieniawski M, Angus B et al. Prognostic significance of immunohistochemistry - based markers and algorithms in immunochemotherapy - treated diffuse large B cell lymphoma patients. Histopathology 2013; 63: 788-801.
  39. Visco Y, Li Y, Xu-Monette Z.Y et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Prorram Study. Leukemia 2012.
  40. Troppan K, Wenzl K, Deutsch A et al. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2014; 34: 557-64.
  41. Guo Y, Takeuchi I, Karnan S et al. Array - comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows distinct genomic alterations. Cancer Sci 2014; 105 (4): 481-9.
  42. Scott D.W, Wright G.W, Williams P.M et al. Determining cell - of - origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin - fixed paraffin - embedded tissue. Blood 2014; 123 (8): 1214-7.
  43. Deffenbacher K.E, Iqbal J, Sanger W et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood 2012; 119 (16): 3757-66.
  44. Мисюрина А.Е., Мисюрин В.А., Барях Е.А., Ковригина А.М. Роль экспрессии генов C-MYC, BCL2, BCL6 в патогенезе диффузной В-крупноклеточной лимфомы. Клин. онкогематология. 2014; 7 (4): 512-21.
  45. Johnson N.A, Slack G.W, Savage K.J et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphomide, doxorubicin, vincristine and prednisone. J Clinical Oncol 2012; 30 (28): 3452-8.
  46. Perry A.M, Alvarado-Bernal Y, Laurini J.A et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014; 165: 382-91.
  47. Valera A, Lopez-Guillermo A, Cardesa-Salzmann T et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013; 98 (10): 1554-62.
  48. Horn H, Ziepert M, Becher C et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B cell lymphoma. Blood 2013; 121: 2253-63.
  49. Tzankov A, Xu-Monette Z, Gerhard M et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathol 2014; 27: 958-71.
  50. Visco C, Tzankov A, Xu-Monette Z et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP consortium program study. Haematologica 2013; 98 (2): 255-63.
  51. Hu S, Xu-Monette Z.Y, Balasubramanyam A et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013; 121: 2715-24.
  52. Ok C.J, Xu-Monette Z.Y, Tzankov A et al. STAT3 expression and clinical inplications in de novo diffuse large B cell lymphoma: a report from the International DLBCL Rituximab-CHOP consortium program. Blood 2013; 122: 21.
  53. Wu Z.L, Song Y.Q, Shi Y.F et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma.J Hematol Oncol 2011; 4 (31): 1-6.
  54. Ok C.Y, Chen J, Xu-Monette Z et al. Clinical implications of phosphorylated STAT3 expre ssion in de novo diffuse large B-cell lymphoma. Clin Cancer Res 2014.
  55. Soldini D, Montagna C, Schuffer P et al. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Ann Oncol 2013; 24: 193-201.
  56. Aquino G, Marra L, De Chiara A et al. MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas. Infect Agents Cancer 2013; 8: 37.
  57. Dunleavy K, Pittaluga S, Shovlin M et al. Concurrent expression of MYC/BCL2 protein in newly diagnosed DLBCL is not associated with an inferior survival following EPOCH-R therapy. Blood 2013; 122: 21.
  58. Мисюрина А.Е., Ковригина А.М., Барях А.Е. Экспрессия белков MYC и BCL2 у больных с диффузной В-крупноклеточной лимфомой. Клин. онкогематология. 2015; 8 (1): 44-53.
  59. Ichikava S, Fukuhara N, Katsushima H et al. Association between BACH2 expression and clinical prognosis in diffuse large B cell lymphoma. Cancer Sci 2014; 105 (4): 437-44.
  60. Yamamoto W et al. Human leukocyte antigen - DR expression on flow cytometry and tumor associated macrophages in diffuse large B cell lymphoma treated by: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cogort study. Leukemia/Lymphoma 2014; 55 (12): 2721-7.
  61. Miyazaki K. Yamaguchi M, Suzuki R et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 2011; 22: 1601-7.
  62. Laurent C, Do C, Gascoyne R.D et al. Anaplastic lymphoma kinase - positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009; 27 (25): 4211-6.
  63. Valera A, Colomo L, Martinez A et al. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Modern Pathol 2013; 26: 1329-37.
  64. Cox C.M, Di Napoli A., Scarpino S et al. Clinicopathologic characterization of diffuse large B cell lymphoma with an associated serum monoclonal IgM component.
  65. Roschewski M, Dunleavy K, Wilson W.H. Diffuse large B-cell lymphoma: molecular targeted therapy. Int J Hematol 2012; 96 (5): 552-61.
  66. Horie R. Molecularly - targeted strategy and NFkB in lymphoid malignancies. J Clin Experiment Hematopathol 2013; 53 (3): 185-95.
  67. Roschewski M, Staudt L.M, Wilson W.H. Diffuse large B-cell lymphoma - treatment approaches in the molecular era. Nature. Reviews. Clin Oncol 2014; 11 (1): 12-23.
  68. Nagel D, Vincendeau M, Eitelhuber A.C et al. Mechanisms and consequences of constitutive NFkB activation in B-cell lymphoid malignancies. Oncogene 2014; p. 1-11.
  69. Schneider C, Pasqualucci L, Dalla-Favera R. Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagnost Pathol 2011; 28: 167-77.
  70. Witzig T.E et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25: 341-7.
  71. Furman R.R, Martin P, Ruan J et al. Phase1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010; p. 5432-9.
  72. Ruan J, Martin P, Furman R.R et al. Bortezomib plus CHOP-Rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clinical Oncol 2011; 29 (6): 690-7.
  73. Maishman T, Stanton L, Davies A et al. A novel adaptive trial design: randomized evaluation of molecular guided therapy for diffuse large B-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy. Trials 2013; 14: 77.
  74. Johnston P.B et al. Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study (NCCTG N1085). J Clin Oncol 2015; 33 (Suppl.; abstr 8518).
  75. Nam S.J et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leukemia Lymphoma 2014; 55 (11): 2466-76.
  76. Xie M et al. The prognostic significance of tumor - associated macrophages and NK cells in patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2014; 124 (21).
  77. Togunaga T, Tomita A, Sugimoto K et al. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry - positive and flow cytometry - negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. Cancer Sci 2014; 105 (1): 35-43.
  78. Song G, Cho W.C, Gu L et al. Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Med Oncol 2014.
  79. Fen Liu et al. FCGR3A 158 V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol 2014; 33: 616-23.
  80. Morschhauser F.A et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the Phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-9.
  81. Coiffier B et al. A multicentre, phase II trial ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Hematol 2013; 163: 334-42.
  82. Bartlett N et al. Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high - intermediate/high - risk diffuse large B-cell lymphoma (DLBCL). J Clinl Oncol 2015; 33 (Suppl.; abstr 8506).
  83. Younes A, Bartlett N.L, Leonard J.P et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363: 1812-21.
  84. Pro B et al. Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large - cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30 (18): 2190-6.
  85. http://www.childrensoncologygroup.org. A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117.
  86. Wagner-Johnston N.D et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B cell lymphoma. Leukemia Lymphoma 2015; p. 1-7.
  87. Гаврилина О.А., Габеева Н.Г., Морозова А.К. Роль высокодозной химиотерапии и аутотрансплантации стволовых клеток крови у пациентов с диффузной В крупноклеточной лимфомой. Терапевт. арх. 2013; 7: 90-7.
  88. Rytting M et al. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Ped Blood Cancer 2014; 61 (2): 369-72.
  89. Friedberg J et al. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Hematol 2014; 166 (3): 382-9.
  90. Briones J et al. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica 2014; 99 (3): 505-10.
  91. Cooney-Qualter E et al. A phase I study of yttrium-90 ibritumomab tiuxitan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin lymphoma: a Children’s Oncology Group Study. Clin Cancer Res 2007; 13: 5652-60.
  92. Kraeber-Bodere F et al. Consolidation anti-CD22 fractionated radioimmunotherapy (RIT) with 90Y- epratuzumab tetraxetan following R-CHOP in elderly diffuse large B cell lymphoma (DLBCL) patients. J Nucl Med 2013; 54 (Suppl. 2): 179.
  93. Witzig T.E et al. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica 2014; 99 (11): 1738-45.
  94. Viardot A et al. Treatment of relapsed/refractory diffuse large B cell lymphoma with the bispecific T-cell engager (BiTE) antibody construct blinatumomab: primary analysis results from an open - label, phase II study. ASH annual meeting abstracts book, 2014; p. 4460.
  95. Portell C.A et al. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol Adv Appl 2013; 5: 5-11.
  96. Schlegel P et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014; 99 (7): 1212-18.
  97. Stackelberg A et al. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. ASH annual meeting abstracts book, 2014; p. 2292.
  98. Schuster F.R et al. Immunotherapy with trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in pediatric high - risk patients with recurrent CD20-positive B-cell malignancies. Br J Haematol 2015; 169 (1): 90-102.
  99. Kochenderfer J.N et al. Chemotherapy - refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014; p. 1-11.
  100. Wang Y et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor - modified T cells. Clin Immunol 2014; 155: 160-75.
  101. Maude S et al. Chimeric antigen receptor (CAR) modified N cells induce durable remissions in children with relapsed/refractory ALL. ASPHO annual meeting book, 2015; p. 4003.
  102. Suzuki M et al. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Ped Blood Cancer 2015; 62: 1326-36.

© ООО "Консилиум Медикум", 2015

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах